News Releases

  • TOP
  • News Releases
  • 2022
  • Taiho Pharmaceutical Obtains Approval to Manufacture and Market HSP90 inhibitor Jeselhy® Tablets 40 mg (Pimitespib) for Gastrointestinal Stromal Tumor (GIST)
June 20, 2022
Taiho Pharmaceutical Co., Ltd.

Taiho Pharmaceutical Obtains Approval to Manufacture and Market HSP90 inhibitor Jeselhy® Tablets 40 mg (Pimitespib) for Gastrointestinal Stromal Tumor (GIST)

Taiho Pharmaceutical Co., Ltd. announced today that it has obtained manufacturing and marketing approval from Japan’s Ministry of Health, Labour and Welfare for the oral heat shock protein (HSP) 90 inhibitor Jeselhy® Tablets 40 mg (generic name: pimitespib; development code: TAS-116), for the indication of gastrointestinal stromal tumor (GIST) that has progressed after chemotherapy.

Jeselhy®, a compound discovered by Taiho Pharmaceutical, inhibits HSP90, thereby showing an antitumor effect by destabilizing and reducing proteins such as KIT, PDGFRA, HER2, and EGFR which are involved in the growth and survival of cancer.

The approval is based on the results of a Phase III trial (CHAPTER-GIST-301 trial) comparing the efficacy and safety of pimitespib versus placebo in patients with previously treated GIST. In the trial, pimitespib prolonged progression-free survival (PFS), the primary endpoint, and demonstrated adverse events were manageable. The results of this study were published in the Annals of Oncology. *1

Taiho Pharmaceutical will promote the proper use of Jeselhy® Tablets for treating GIST, for which there are major unmet medical needs, to ensure that it can contribute to the needs of patients with GIST and healthcare professionals.

About CHAPTER-GIST-301 Trial

This was a randomized, double-blind, PhaseIII, clinical trial comparing pimitespib with placebo in patients with GIST judged to be refractory to or intolerant of standard treatments. The primary endpoint in this trial was PFS, and the secondary endpoint measures included overall survival (OS) and safety, as well as quality of life (QOL). Eighty-six GIST patients who were at least 20 years old, and had previously been treated with imatinib, sunitinib, and regorafenib, were enrolled between October 2018 and April 2020 from six Japanese medical institutions specialized in GIST.

For more information on the CHAPTER-GIST-301 trial, please visit (JapicCTI-184094)


About GIST (Gastrointestinal Stromal Tumor)

GIST develops in the walls of the gastrointestinal tract (frequently in the stomach and small intestine and rarely in the large intestine and esophagus) and is a type of malignant tumor (sarcoma) that causes metastasis and relapses. It has different characteristics than gastric and colorectal cancers that develop from mucous membrane.*2 The incidence in Japan is estimated to be roughly 1,500 to 2,500 patients per year (calculated based on the annual incidence rate reported in different countries),*3 making it a rare cancer. In many cases of GIST, there are mutations in the KIT and PDGFRA genes, which are involved in the growth and survival of cancer. All GIST treatments approved by the three regulatory authorities of Japan’s Ministry of Health, Labour and Welfare, the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA) have as their main mechanism of action the inhibition of receptor tyrosine kinases KIT and PDGFRA. There is an unmet medical need for a therapeutic agent to treat GIST that remains after treatment with the drugs currently approved.

About HSP90 (Heat Shock Protein 90)

Cells are constantly exposed to various stresses within the body. Cancer cells in particular are exposed to a lot of stress in the form of hypoxia, malnutrition, elimination by the immune system, and genetic instability. Expression of HSP90 increases in response to stress, protecting cells from stress and promoting cell survival by maintaining the structural and functional integrity of proteins.

HSP90 is overexpressed and exists in a highly active state in cancer cells and tumor tissue, where it is known to be especially important in the survival and maintenance of cancer. Furthermore, it has been reported that the expression of HSP90 in GIST, bladder cancer, acute myelocytic leukemia, breast cancer, non-small cell lung cancer, colorectal cancer, and melanoma correlates with cancer progression and/or a patient’s prognosis. *4

*1: References

Kurokawa Y, Honma Y, Sawaki A, Naito Y, Iwagami S, Komatsu Y, et al. Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase 3 trial. Ann Oncol. 2022. doi: 10.1016/j.annonc.2022.05.518.

*2: See the Cancer Information Service of the National Cancer Center Japan (in Japanese).

*3: References

1.Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M, Herings RM, Hogendoorn PC. Incidence of gastrointestinal stromal tumours is underestimated: Results of a nation-wide study. Eur J Cancer. 2005;41:2868-2872.

2.Tryggvason G, Gíslason HG, Magnússon MK, Jónasson JG. Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer. 2005;117:289-293.

3.Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden. Cancer. 2005;103:821-829.

4.Chan KH, Chan CW, Chow WH, Kwan WK, Kong CK, Mak KF, et al. Gastrointestinal stromal tumors in a cohort of Chinese patients in Hong Kong. World J Gastroenterol. 2006;12:2223-2228.

*4: References

1.Li CF, Huang WW, Wu JM, Yu SC, Hu TH, Uen YH, et al. Heat shock protein 90 overexpression independently predicts inferior disease-free survival with differential expression of the alpha and beta isoforms in gastrointestinal stromal tumors. Clin Cancer Res. 2008;14:7822-7831.

2.Lebret T, Watson RW, Molinié V, O'Neill A, Gabriel C, Fitzpatrick JM, et al. Heat shock proteinsHSP27, HSP60, HSP70, and HSP90: expression in bladder carcinoma. Cancer. 2003;98:970-977

3.Thomas X, Campos L, Mounier C, Cornillon J, Flandrin P, Le QH, et al. Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia. Leuk Res.2005;29:1049-1058.

4.Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, et al. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res. 2007;67:2932-2937.

5.Gallegos Ruiz MI, Floor K, Roepman P, Rodriguez JA, Meijer GA, Mooi WJ, et al. Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One. 2008;3:e0001722.

6. Milicevic Z, Bogojevic D, Mihailovic M, Petrovic M, Krivokapic Z. Molecular characterization ofhsp90 isoforms in colorectal cancer cells and its association with tumour progression. Int J Oncol.2008; 32:1169-1178.

7.McCarthy MM, Pick E, Kluger Y, Gould-Rothberg B, Lazova R, Camp RL, et al. HSP90 as a marker of progression in melanoma. Ann Oncol. 2008;19:590-594.

Product Information

Product name

Jeselhy® Tablets 40mg

Generic name



GIST that has progressed after chemotherapy

Dosage and administration

The usual dosage of 160 mg (as the pimitespib dose) for adults, once a day in the fasting conditions.
The oral administration is once a day for 5 consecutive days, followed by a 2-day rest, repeating this cycle subsequently. Dosage should be reduced based on the patient's condition.

Information in this news release was current as of the original release date.

Taiho Pharmaceutical's press releases may contain information about prescription drugs including products currently under development, however information contained in the press releases are not intended to constitute promotion, advertisement, or medical advice.

  • TOP
  • News Releases
  • 2022
  • Taiho Pharmaceutical Obtains Approval to Manufacture and Market HSP90 inhibitor Jeselhy® Tablets 40 mg (Pimitespib) for Gastrointestinal Stromal Tumor (GIST)